Douglas Hunt B.Sc., FRAPS Net Worth

The estimated Net Worth of Douglas M Hunt is at least $2.78 Milhão dollars as of 17 July 2024. Mr Hunt owns over 3,637 units of Puma Biotechnology Inc stock worth over $333,068 and over the last 7 years he sold PBYI stock worth over $307,677. In addition, he makes $2,135,437 as Sr. VP of Regulatory Affairs e Medical Writing & Project Management at Puma Biotechnology Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr FRAPS PBYI stock SEC Form 4 insiders trading

Mr has made over 33 trades of the Puma Biotechnology Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,637 units of PBYI stock worth $13,457 on 17 July 2024.

The largest trade he's ever made was selling 8,358 units of Puma Biotechnology Inc stock on 3 January 2024 worth over $37,527. On average, Mr trades about 1,435 units every 44 days since 2018. As of 17 July 2024 he still owns at least 133,227 units of Puma Biotechnology Inc stock.

You can see the complete history of Mr Hunt stock trades at the bottom of the page.

Mr. Douglas Hunt B.Sc., FRAPS biography

Douglas Hunt B.Sc., FRAPS is the Sr. VP of Regulatory Affairs, Medical Writing & Project Management at Puma Biotechnology Inc.

What is the salary of Mr FRAPS?

As the Sr. VP of Regulatory Affairs e Medical Writing & Project Management of Puma Biotechnology Inc, the total compensation of Mr FRAPS at Puma Biotechnology Inc is $2,135,437. There are 3 executives at Puma Biotechnology Inc getting paid more, with Alan H. Auerbach having the highest compensation of $5,693,423.

How old is Mr FRAPS?

Mr FRAPS is 56, he's been the Sr. VP of Regulatory Affairs e Medical Writing & Project Management of Puma Biotechnology Inc since . There are 6 older and 8 younger executives at Puma Biotechnology Inc. The oldest executive at Puma Biotechnology Inc is Jay Moyes, 66, who is the Lead Independent Director.

What's Mr FRAPS's mailing address?

Douglas's mailing address filed with the SEC is C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES, CA, 90024.

Insiders trading at Puma Biotechnology Inc

Over the last 12 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo, eTroy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.

What does Puma Biotechnology Inc do?

we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.

Complete history of Mr Hunt stock trades at Puma Biotechnology Inc

Puma Biotechnology Inc executives and stock owners

Puma Biotechnology Inc executives and other stock owners filed with the SEC include:

• Alan H. Auerbach,
  Founder, Chairman, Pres, CEO & Sec.
• Jeffrey Jerome Ludwig,
  Chief Commercial Officer
• Alan Auerbach,
  Chairman of the Board, President, Chief Executive Officer
• Douglas Hunt B.Sc., FRAPS,
  Sr. VP of Regulatory Affairs, Medical Writing & Project Management
• Maximo F. Nougues,
  CFO & Principal Accounting Officer
• Douglas Hunt,
  Senior Vice President, Regulatory Affairs, Medical Writing and Project Management
• Richard Bryce,
  Chief Medical and Scientific Officer
• Ann Miller,
  Independent Director
• Dr. Richard P. Bryce,
  Chief Medical & Scientific Officer
• Maximo Nougues,
  Chief Financial Officer
• Hugh O Dowd,
  Independent Director
• Jay Moyes,
  Lead Independent Director
• Troy Wilson,
  Independent Director
• Adrian Senderowicz,
  Independent Director
• Michael Miller,
  Independent Director
• Mariann Ohanesian,
  IR Contact Officer
• Brian Stuglik,
  Director
• Dr. Alvin F. Wong,
  Chief Scientific Officer
• Charon Spencer Sr.,
  VP of HR
• Steven Lo,
  Chief Commercial Officer
• Capital Partners Gp, L.L.C....,
  
• Robert Charnas,
  
• Richard Benton Phillips,
  SEE REMARKS
• Charles R Eyler,
  SEE REMARKS
• Frank Zavrl,
  Director
• Thomas Malley,
  Director
• Jeffrey Jerome Ludwig,
  Chief Commercial Officer
• Alvin F Wong,
  Chief Scientific Officer
• Allison Dorval,
  Director
• Alessandra Cesano,
  Director